linjc16/ctgov huggingface dataset:
The Interaction Between Appetite Hormones

Study Overview
=================
Brief Summary
-----------------
Glucagon Like Peptide (GLP) -1 affects metabolic response corrected for weight change

Detailed Description
-----------------
Many obese people have had several successful weight losses, however very few can maintain the weight loss over a longer period (e.g. one year) Therefore, we want to investigate the metabolic response and the importance for maintenance of weight loss in obese people, who lost at least 7, 5 % body weight by low calorie diet followed by 52 weeks of diet weight maintenance with or without supplement of GLP-1.

Official Title
-----------------
The Interaction Between Appetite Hormones and Their Importance for Maintenance of Weight Loss After a Low Calorie Diet

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: GLP-1
* Dietary Supplement: low calorie diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI > 30 and < 40 (kg/m2) Healthy Exclusion Criteria: Other known illness Medicine that affects glucose- and lipid metabolism, appetite or food intake Pregnancy Breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GLP-1<br>GLP-1 and low calorie diet | Other: GLP-1<br>* GLP-1<br>Dietary Supplement: low calorie diet<br>* low calorie diet<br>|
| Experimental: Control<br>low calorie diet | Dietary Supplement: low calorie diet<br>* low calorie diet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in hormone level corrected for weight change |  | Baseline and week 52 |
Heart Rate Variability (HRV) Among Children With Brain Damage

Study Overview
=================
Brief Summary
-----------------
to investigate the function of the autonomic nervous system in children with with post traumatic brain injury and children with cerebral palsy through an analysis of heart rate variability (HRV) occurring with walking performance.

Detailed Description
-----------------
40 children with brain damage (20 with post TBI and 20 with CP)and 40 typically developed children will be participate in this study. ECG signals during rest and walking (for 6 minute and during step climbing) will be recorded.

Official Title
-----------------
Assessment of Autonomic Nervous System With Analysis of Heart Rate Variability in Children With Brain Damage.

Conditions
-----------------
Brain Injury, Cerebral Palsy

Intervention / Treatment
-----------------
* Other: 6 min walk test, Step climbing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: able to walk independently Exclusion Criteria: can not follow simple commands

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years


Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Traumatic brain injury | Other: 6 min walk test, Step climbing<br>* walking for 6 minute and climbing steps<br>|
| Experimental: B<br>Cerebral palsy | Other: 6 min walk test, Step climbing<br>* walking for 6 minute and climbing steps<br>|
| Experimental: C<br>Controls | Other: 6 min walk test, Step climbing<br>* walking for 6 minute and climbing steps<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HRV parameters |  | during the assessment |
Timed Interval Measurement of Eotaxin in Stroke Study

Study Overview
=================
Brief Summary
-----------------
Stroke is caused by sudden changes in blood flow in the brain. This can be fatal or can result in permanent disability. A fast diagnosis is essential to initiate effective interventions and optimize benefits to patients. There are other diseases that can look like a stroke and these are called stroke mimics. The quicker that stroke mimics can be ruled out the faster a stroke can be diagnosed and treatment can be given. The investigators may be able to use chemicals in the blood to rapidly confirm that a person has had a stroke. One such chemical is called eotaxin. Eotaxin has been found to be changed in sufferers of a stroke but not in those with stroke mimics. However, more research is needed to confirm the usefulness of eotaxin. This feasibility study aims to provide the foundations to allow a large scale trial of this test. The study aims to recruit participants that have had a stroke or a stroke mimic from the Acute Stroke Unit and Stroke clinic at the Royal Devon and Exeter Hospital. Up to 6 blood samples will be taken from each participant at different times over one week. Eotaxin will be measured in these samples and in participant's leftover samples taken for clinical care. This is needed because the investigators know that the amount of eotaxin changes in the blood after a stroke but we do not know how quickly this change happens and for how long the change occurs. The study will also allow the investigators to understand how many participants will be needed for a large scale trial and the challenges that may be faced in recruiting participants.

Official Title
-----------------
Timed Interval Measurement of Eotaxin in Stroke Study

Conditions
-----------------
Stroke, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presenting with focal neurological symptoms suggestive of stroke Aged over 18 years Exclusion Criteria: Presenting later than 12 hours after symptom onset Under 18 years of age History of cardiovascular disease (Healthy Controls) History of neurological disease (Healthy Controls) History of stroke mimics (Healthy Controls)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stroke Symptom Participants<br> | |
| Healthy Controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Outcome | Plasma Eotaxin Concentration | 0 to 7 days |
Motivation of Patients Diagnosed With Multiple Sclerosis to Become Citizen Researchers

Study Overview
=================
Brief Summary
-----------------
The study will based on qualitative methods investigate motivational factors among patients diagnosed with multiple sclerosis for registering nutrition, environmental factors, stress provoking factors and physical activity (NESPA). The aim is to gain knowledge on motivational factors for using a digital tool for collecting data on NESPA and incorporate this knowledge into a form which can be used in requirement specifications for such a digital tool.

Official Title
-----------------
Identifying Motivational Factors for Registering Nutrition and Lifestyle Factors Among Patients With Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Other: Qualitative evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or above Read, write and understand Danish Exclusion Criteria: Aphasia Severe cognitive impairment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Semi-structured interviews<br>20 participants (anticipated) | Other: Qualitative evaluation<br> <br> |
| Questionnaire survey<br>400 respondents (anticipated) | Other: Qualitative evaluation<br> <br> |
| Focus group interviews<br>3-5 focus group interviews (anticipated) | Other: Qualitative evaluation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of qualitative interviews and measurement of eHealth literacy (eHealth literacy questionnaire) |  | Up to 6 months | 
| Evaluation of motivational factors based on questionnaire survey |  | Up to 10 months | 
| Analysis of focus group interviews on motivational factors for registering nutrition and lifestyle factors among patients with multiple sclerosis |  | Up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Sclerosis, Qualitative study, Motivation
Angiographic and IVUS Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals (AIFSIDDES)

Study Overview
=================
Brief Summary
-----------------
The safety and efficacy of drug-eluting stents (DES) with a biocompatible polymer have been demonstrated in randomized clinical trials as well as in real world practice. Theoretically, a new DES with a biodegradable polymer should reduce the incidence of late in-stent thrombosis, however, the long-term safety and efficacy of these stents remains unknown. This study was aimed to compare the safety and efficacy of the Excel DES with a biodegradable polymer to the Endeavor DES with a biocompatible polymer in same individuals.

Conditions
-----------------
Percutaneous Coronary Angioplasty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: simultaneous implantation of one or more Endeavor stents and one or more Excel stents during the same index procedure willing to be followed up with coronary angiography and intravascular ultrasound at least one year post-procedure. Exclusion Criteria: Patients were excluded from the study if they had more than two kinds of stents implanted or if the two study stents were implanted during separate interventional procedures or in coronary artery bridge vessel or restenotic lesions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endeavor Segment group<br> | |
| Excel Segment Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
percutaneous coronary angioplasty, zotarolimus-eluting stent, sirolimus-eluting stent, biodegradable polymer, biocompatible polymer
Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device

Study Overview
=================
Brief Summary
-----------------
This clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.

Detailed Description
-----------------
Subjects will collect spectral raman data on device every 15 minutes for 10 hours a day for five days. The five days will be distributes with in a timeframe of ten days. A Flash Glucose Monitor will be used as a comparator. In addition to this, four daily capillary Blood Glucose readings will be collected.

Official Title
-----------------
Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: WM3.4NR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female subjects 18 years of age or older Diabetic patients (all types) Exclusion Criteria: Pregnant women Subjects not able to understand and read Danish In investigator's opinion, subject is not able to follow instructions as specified in the protocol Subjects not able to hold hand/arm steadily Extensive skin changes, tattoos or diseases on probe application site Known allergy to medical grade alcohol used to disinfect skin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IMD data collection<br>Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators. | Device: WM3.4NR<br>* The investigational medical device will collect spectral raman data from tissue.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Generation and validation of predictive calibration models | The collected data will generate individual calibration models capable of predicting tissue glucose concentrations. An evaluation of the models by the consensus error grid will be performed. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety assessment of the intervention by the paucity of adverse events | The number of subjects experiencing device-related adverse events will be recorded. | 3 months |
Effects of Volatile and Intravenous Anesthetics on Pupillary Function

Study Overview
=================
Brief Summary
-----------------
To compare of effects of volatile and intravenous anesthetics on pupillary function during general anesthesia in children

Detailed Description
-----------------
The investigator will measure the pupillary function with pupillometry during general anesthesia with volatile or intravenous anesthetics in children.

Official Title
-----------------
Comparison of Effects of Volatile and Intravenous Anesthetics on Pupillary Function During General Anesthesia in Children; a Prospective Observational Study.

Conditions
-----------------
Pupillary Functions, Abnormal

Intervention / Treatment
-----------------
* Other: sevoflurane
* Other: propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients undergoing general anesthesia Exclusion Criteria: If injection of any agents that can change pupil size or index Any severe side effects, adverse drug reaction

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sevoflurane+Remifentanil<br>Using inhalent agent(Sevoflurane), continuous infusion of Remifentanil | Other: sevoflurane<br>* volatile anesthetic<br>|
| Propofol+Remifentanil<br>Using continuous infusion of Propofol and Remifentanil | Other: propofol<br>* intravenous anesthetic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NPi | Neurological Pupil index | 1hour afer skin incision | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| %CH | % change of pupil size | 1. Stage of loss of consciousness after induction with bolus propofol 2. Before and after tracheal intubation 3. Skin incision 4. 1hour afer skin incision 5. Just before extubation | 
| CV | Constriction Velocity | 1. Stage of loss of consciousness after induction with bolus propofol 2. Before and after tracheal intubation 3. Skin incision 4. 1hour afer skin incision 5. Just before extubation | 
| DV | Dilation Velocity | 1. Stage of loss of consciousness after induction with bolus propofol 2. Before and after tracheal intubation 3. Skin incision 4. 1hour afer skin incision 5. Just before extubation | 
| NPi | Neurological Pupil index | 1. Stage of loss of consciousness after induction with bolus propofol 2. Before and after tracheal intubation 3. Skin incision 4. 1hour afer skin incision 5. Just before extubation |
Evaluation of the Effect of an Ankle Foot Orthoses for Ambulatory Function

Study Overview
=================
Brief Summary
-----------------
The main purpose of this investigation is to evaluate the effect of a lower leg brace on walking efficiency and community walking in people who have weakness in one side of the body caused after a stroke. The evaluation will consist of several tests that will evaluate movement, tightness, balance and sensation in affected leg.

Detailed Description
-----------------
To comprehensively evaluate the effect of an AFO on ambulatory function and loading in hemiplegic gait. This study is addressing important questions regarding the effect of an AFO on gait and introduces technology for quantifiable objective assessment of AFO effectiveness. It will attempt to identify if AFO wear compliance increases community ambulation and walking efficiency bilaterally. Research is needed to fully understand how compliance affects mobility outcomes.

Official Title
-----------------
Comprehensive Evaluations of the Effect of an Ankle Foot Orthoses for Ambulatory Function in Adults With Hemiplegia

Conditions
-----------------
Hemiplegia, Spastic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 18 and 75 Have sustained a stroke at least 6 months prior to study enrollment Use a prescribed custom brace while walking Have no history of injury, orthopedic or other medical problem in the normal leg Be able to walk independently or with close supervision for 25 feet without a brace or cane Wear shoes sizes 5 1/2 - 11 US womens or size 6-13 US mens Exclusion Criteria: Orthopedic problems or history that will interfere with walking or limit the range of motion of legs Neurological illness, history, or conditions that my interfere with walking except for stroke Psychiatric conditions or history that would interfere with the ability to walk or follow directions Serious lung or heart condition that could severely limit the ability to walk

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stroke, Hemiplegia, AFO, Gait
Use of NovoSeven® in Active Variceal Bleeding

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.

Official Title
-----------------
Effectiveness and Safety of Use of NovoSeven® in the Treatment of Active Variceal Bleeding in Patients With Advanced Cirrhosis

Conditions
-----------------
Acquired Bleeding Disorder, Cirrhosis

Intervention / Treatment
-----------------
* Drug: activated recombinant human factor VII


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Variceal bleeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: activated recombinant human factor VII|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment failure |  | Within 5 days after first trial product administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  |  | 
| Rebleeding |  |  | 
| Control of acute bleeding |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Active variceal bleeding in patients with advanced cirrhosis